Table 10.6h

Persistency of Discharge Regimen by Follow-up Period, 2001 to 2005

Recipients with Intestine Transplants

  Year of Transplant
2001 2002 2003 2004 2005
Discharge Regimen (w/ or w/o Steroid Use) Tac+Aza At Discharge (N) 6 - - - -
At Discharge (%) 100.0% - - - -
6 Months PostTx (%) 100.0% - - - -
1 Year PostTx (%) 83.3% - - - -
2 Years PostTx (%) 50.0% - - - -
3 Years PostTx (%) 25.0% - - - -
Tac+MMF At Discharge (N) 3 8 7 11 17
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
6 Months PostTx (%) 100.0% 87.5% 71.4% 80.0% 76.5%
1 Year PostTx (%) 100.0% 50.0% 57.1% 70.0% 52.9%
2 Years PostTx (%) 0.0% 50.0% 57.1% 70.0% -
3 Years PostTx (%) 0.0% 50.0% 42.9% - -
Tac+Siro At Discharge (N) 18 14 4 14 18
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
6 Months PostTx (%) 88.2% 85.7% 75.0% 71.4% 83.3%
1 Year PostTx (%) 82.4% 78.6% 0.0% 50.0% 54.2%
2 Years PostTx (%) 63.3% 57.1% 0.0% 50.0% -
3 Years PostTx (%) 50.7% 42.9% 0.0% - -


Source: OPTN/SRTR Data as of May 1, 2007.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.